Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
60.06 USD | -0.40% | -0.92% | -4.36% |
Apr. 25 | Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing | MT |
Apr. 22 | Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.36% | 6.53B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.67% | 22.02B | |
-17.84% | 20.9B | |
-9.37% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- PCVX Stock
- News Vaxcyte, Inc.
- Vaxcyte Initiates Dosing in Second Part of Phase 1/2 Trial of VAX-24 in Invasive Pneumococcal Disease, Pneumonia.